Regenerative medicine最新文献_第5页

Three intra-articular injections of allogeneic umbilical cord-derived mesenchymal stromal cells in knee osteoarthritis: a phase-I clinical trial. 三次关节内注射异体脐带间充质细胞治疗膝关节骨关节炎：一项i期临床试验

IF 3 4区医学

Regenerative medicine Pub Date : 2026-01-01 Epub Date: 2026-02-27 DOI: 10.1080/17460751.2026.2636683

Elaheh Khodadoust, Morteza Zarrabi, Elahe Afzal, Fatemeh Zamani, Masoumeh Nouri, Safdar Masoumi, Seyedeh Malihe Mahmoodi, Faeze Sharafi, Maedeh Alizadeh, Mohsen Emadedin, Massoud Vosough

{"title":"Three intra-articular injections of allogeneic umbilical cord-derived mesenchymal stromal cells in knee osteoarthritis: a phase-I clinical trial.","authors":"Elaheh Khodadoust, Morteza Zarrabi, Elahe Afzal, Fatemeh Zamani, Masoumeh Nouri, Safdar Masoumi, Seyedeh Malihe Mahmoodi, Faeze Sharafi, Maedeh Alizadeh, Mohsen Emadedin, Massoud Vosough","doi":"10.1080/17460751.2026.2636683","DOIUrl":"10.1080/17460751.2026.2636683","url":null,"abstract":"Purpose: This phase I clinical trial evaluated the safety and preliminary efficacy of three intra-articular injections of 20 × 106 allogeneic Umbilical Cord-derived Mesenchymal Stromal Cells (UC-MSCs) in patients with Knee Osteoarthritis (OA) at a two-month interval.Methods: Six participants aged 40-70 years with Kellgren and Lawrence grade II-III were enrolled. They received three bilateral intra-articular injections of allogeneic UC-MSCs at two-month intervals. They were assessed for possible Adverse Events, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Visual Analogue Scale (VAS), Short Form Health Survey, and Magnetic Resonance Imaging (MRI) over 12 months.Results: No serious adverse events occurred. Four participants (66%) reported at least one adverse event, most commonly transient injection-site pain or swelling. Exploratory analyses showed improvement in WOMAC scores from a median of 58.33 (IQR: 25-69.53) at baseline to 21.85 (IQR: 11.97-61.44) at 12 months, with pain and function improving in five patients (83%). VAS scores decreased by a median of 55% (IQR: -62.5 to -12.5). MRI showed no consistent structural changes, although mild tibial cartilage improvement was observed in two participants.Conclusion: Three intra-articular injections of allogeneic UC-MSCs appear to be safe and may provide functional benefits in patients with knee OA, supporting further investigation in larger, controlled trials.Clinical trial registration: https://irct.behdasht.gov.ir identifier is IRCT20211102052944N1.","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"21-33"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13011591/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147309583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quality control strategy for differentiating induced pluripotent stem cells into pancreatic β-cells before transplantation. 诱导多能干细胞移植前分化为胰腺β细胞的质量控制策略。

IF 3 4区医学

Regenerative medicine Pub Date : 2026-01-01 Epub Date: 2026-03-11 DOI: 10.1080/17460751.2026.2634720

Francisco Sotomayor Lugo, Mays Amer Abuhantash, Gisela Maria Suarez Formigo, Sharmin Haideri, Lucia Tomiyama, Grinand Luc, Masaru Niidate, Liping Sun, Nataly Iglesias Barrameda, Tania Grinan Ramirez, Yendry Ventura Carmenate

{"title":"Quality control strategy for differentiating induced pluripotent stem cells into pancreatic β-cells before transplantation.","authors":"Francisco Sotomayor Lugo, Mays Amer Abuhantash, Gisela Maria Suarez Formigo, Sharmin Haideri, Lucia Tomiyama, Grinand Luc, Masaru Niidate, Liping Sun, Nataly Iglesias Barrameda, Tania Grinan Ramirez, Yendry Ventura Carmenate","doi":"10.1080/17460751.2026.2634720","DOIUrl":"10.1080/17460751.2026.2634720","url":null,"abstract":"Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease characterized by the destruction of pancreatic β-cells and the subsequent loss of insulin production. The regeneration of pancreatic β-cells from induced pluripotent stem cells (iPSCs) represents a promising therapeutic approach for restoring β-cell function in T1DM patients. However, ensuring the safety, functionality, and genetic stability of iPSC-derived β-cells is crucial for their clinical application. To address this challenge, a comprehensive literature review was conducted using PubMed/MEDLINE, Web of Science, and Scopus databases to identify relevant studies published up to October 2025. It included an analysis of key regulatory documents from the U.S. Food and Drug Administration (FDA), the European Medicines Agency on Advanced Therapy Medicinal Products (EMA ATMP), and the International Organization for Standardization (ISO). This article proposes a comprehensive quality control (QC) strategy for differentiating iPSCs into pancreatic β-cells, emphasizing a tiered approach with multiple checkpoints throughout the process. The strategy integrates advanced molecular and functional assays to evaluate cell identity, viability, stability, and microbiological safety. The proposed QC framework allows for continuous monitoring, early detection of potential issues, and real-time adjustments to optimize the differentiation process. The flexibility of this approach ensures its adaptation to emerging scientific advancements and regulatory requirements. This integrated and adaptable QC strategy enhances the likelihood of success in generating functional β-cells, laying a solid foundation for the clinical application of iPSC-derived β-cell therapies and offering hope for effective, long-term treatments for T1DM.","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"67-89"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13011608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147435072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunogenicity of induced pluripotent stem cell-derived smooth muscle cells results from a reduction in the expression of indoleamine 2,3 dioxygenase (IDO-1). 诱导多能干细胞来源的平滑肌细胞的免疫原性是由于吲哚胺2,3双加氧酶（IDO-1）的表达减少。

IF 3 4区医学

Regenerative medicine Pub Date : 2026-01-01 Epub Date: 2026-02-25 DOI: 10.1080/17460751.2026.2631599

Katherine Partridge, Vera J Mehler, Chris J Burns, Jordan S Pober, Melanie L Moore

{"title":"Immunogenicity of induced pluripotent stem cell-derived smooth muscle cells results from a reduction in the expression of indoleamine 2,3 dioxygenase (IDO-1).","authors":"Katherine Partridge, Vera J Mehler, Chris J Burns, Jordan S Pober, Melanie L Moore","doi":"10.1080/17460751.2026.2631599","DOIUrl":"10.1080/17460751.2026.2631599","url":null,"abstract":"Background: Smooth muscle cells (SMCs) derived from allogeneic induced pluripotent stem cells (iPSC) hold significant potential in cellular therapy for many cardiovascular diseases. However, their immunological profile is poorly characterized, limiting their clinical progression.Aims: This study aimed to investigate the immunogenicity of iPSC-SMC in comparison with naturally derived vascular SMCs (v-SMCs).Result: We found iPSC-SMCs, in contrast to naturally derived vascular SMCs (v-SMC), triggered T effector memory (TEM) cell proliferation. However, expression of TEM activation-related proteins was comparable between both cell types. Since arterial v-SMCs can also establish immunoprivilege through indoleamine 2,3 dioxygenase (IDO-1) activity, we therefore investigated IDO-1 expression in two independently engineered iPSC-SMCs (NIBSC 8 (N8) and Yale 6 (Y6)). IDO-1 expression and functionality was markedly reduced in both iPSC-SMC lines compared to v-SMC and unlike v-SMC, neither iPSC-SMC line could modulate the immune response in a co-culture with CD3/CD28 activated peripheral blood mononuclear cells (PBMC).Conclusions: These results indicate that iPSC-SMC's impaired ability to modulate the immune response through IDO-1 expression contributes to their differing immunogenicity to v-SMC and highlights the importance of immune phenotyping for therapeutic applications of iPSC-derivatives.","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"9-20"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13011584/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147285020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intraparenchymal stem cell transplantation for spinal cord injury: a review of clinical trials. 髓实质内干细胞移植治疗脊髓损伤：临床研究综述。

IF 3 4区医学

Regenerative medicine Pub Date : 2026-01-01 Epub Date: 2026-02-20 DOI: 10.1080/17460751.2026.2631270

Mickey E Abraham, Felicia Song, Adam Glasser, Grant Lieberman, Joel R Martin, Joseph D Ciacci

{"title":"Intraparenchymal stem cell transplantation for spinal cord injury: a review of clinical trials.","authors":"Mickey E Abraham, Felicia Song, Adam Glasser, Grant Lieberman, Joel R Martin, Joseph D Ciacci","doi":"10.1080/17460751.2026.2631270","DOIUrl":"10.1080/17460751.2026.2631270","url":null,"abstract":"Traumatic spinal cord injury (SCI) results in severe and often permanent motor, sensory, and autonomic impairment, and current treatments offer limited restorative benefit. Stem-cell based approaches have been investigated to promote neural repair, but peripheral delivery is limited by poor cell localization and engraftment. Intraparenchymal (IP) transplantation, which delivers cells directly into injured spinal cord, is intended to improve local retention, survival, and integration. This review synthesizes early-phase clinical trials from the United States, Canada, Europe, and Australia, evaluating five major cell platforms: autologous olfactory-ensheathing-cells (OECs), fetal-derived neural stem cells (HuCNS-SC), embryonic stem cell derived oligodendrocyte progenitors (OPC1), fetal spinal cord derived neural progenitor cells (NSI-566), and autologous Schwann cells (ahSCs). IP delivery demonstrates convergent early-phase safety, with no recurrent cell-related severe toxicity, tumor formation, or progressive neurological deterioration attributable to the delivery platform. Functional outcomes remain heterogeneous and modest. Large, reproducible neurological recovery has not been observed, although some studies report limited sensory improvements, isolated motor gains, or electrophysiologic evidence of conduction across or below the injury. These findings support biological activity but insufficient functional efficacy under current trial designs. Future progress will require controlled efficacy studies with standardized endpoints, optimized timing and dosing, and rehabilitation or neuromodulatory integration.","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"55-66"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13011616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146228607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Industry updates from the field of stem cell research and regenerative medicine in September 2025. 2025年9月来自干细胞研究和再生医学领域的行业更新。

IF 3 4区医学

Regenerative medicine Pub Date : 2026-01-01 Epub Date: 2025-11-04 DOI: 10.1080/17460751.2025.2583912

Dusko Ilic, Mirjana Liovic

引用次数: 0

Three-dimensional bio-printed microtissues: precision medicine approach in primary liver cancer. 三维生物打印微组织：原发性肝癌的精准医学方法。

IF 2.6 4区医学

Regenerative medicine Pub Date : 2025-12-01 Epub Date: 2025-11-27 DOI: 10.1080/17460751.2025.2595850

Hani Keshavarz Alikhani, Homeyra Seydi, Kosar Nouri, Fatemeh Majidi, Olga Smirnova, Zahra Heydari, Daria Kuznetsova, Anastasia Shpichka, Elham Rismani, Peter Timashev, Massoud Vosough

{"title":"Three-dimensional bio-printed microtissues: precision medicine approach in primary liver cancer.","authors":"Hani Keshavarz Alikhani, Homeyra Seydi, Kosar Nouri, Fatemeh Majidi, Olga Smirnova, Zahra Heydari, Daria Kuznetsova, Anastasia Shpichka, Elham Rismani, Peter Timashev, Massoud Vosough","doi":"10.1080/17460751.2025.2595850","DOIUrl":"10.1080/17460751.2025.2595850","url":null,"abstract":"Despite remarkable progress in the clinical management of hepatocellular carcinoma (HCC), complications such as heterogenicity of HCC cells and characteristics of cancer stem cells (CSCs) contribute to frequent relapse and treatment resistance. Lack of proper in vitro models has limited developing novel approaches to evaluate innovative therapeutic settings to overcome these challenges. To address current limitations for mimicking cancer microenvironments; various three-dimensional (3D) platforms have been developed, such as tumoroids, patient-derived xenograft (PDX) models, microfluidics-based cancer chip devices, and bio-printed microtissues. Notably, 3D bio-printing technology has enabled researchers to produce scalable complex multicellular tissue models with accurate matrix composition and cellular organization. These microtissues provide precise platforms studying liver regeneration pathways, fibrosis reversal, and cellular responses to therapeutic interventions. This paper, a systematic literature search of databases covering publications from 2000 to 2025, uniquely highlights how these advances enable precise recapitulation of tumor heterogeneity and microenvironmental complexity, thereby offering transformative platforms for personalized drug screening and elucidating mechanisms of liver tissue repair and regeneration. We discussed current challenges and future directions for translating 3D bio-printed liver models into clinically relevant tools, potentially accelerating therapeutic advances and their potential applications in regenerative medicine in terms of personalized medicine and drug screening.","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"773-787"},"PeriodicalIF":2.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12915778/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145638170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the utility of a patient and public involvement and engagement (PPIE) end-of-trial event to re-engage with cell-based therapy participants. 评估患者和公众参与和参与（PPIE）试验结束事件的效用，以重新参与细胞治疗参与者。

IF 3 4区医学

Regenerative medicine Pub Date : 2025-12-01 Epub Date: 2025-12-18 DOI: 10.1080/17460751.2025.2601546

Deepak Menon, Jan-Herman Kuiper, Andrea Bailey, Michael Murphy, Yumna Ladha, Peter Gallacher, Paul Jermin, Andrew Roberts, Geraint Thomas, Charlotte H Hulme, Karina T Wright

{"title":"Evaluating the utility of a patient and public involvement and engagement (PPIE) end-of-trial event to re-engage with cell-based therapy participants.","authors":"Deepak Menon, Jan-Herman Kuiper, Andrea Bailey, Michael Murphy, Yumna Ladha, Peter Gallacher, Paul Jermin, Andrew Roberts, Geraint Thomas, Charlotte H Hulme, Karina T Wright","doi":"10.1080/17460751.2025.2601546","DOIUrl":"10.1080/17460751.2025.2601546","url":null,"abstract":"Aims: Although research in cell-based therapy is expanding, little is known about patient experience in cell therapy trials to-date. This study explores the experience and attitudes of participants involved in the ASCOT randomized controlled trial, a long-term orthopedic study comparing different cell therapies for the treatment of knee articular cartilage defects.Methods: The clinical and rehabilitation experience of participants, and their attitudes relating to i) patient and public involvement (PPIE) in research and ii) future research on cellular therapy and clinical trials were explored through questionnaires. To gather this information, the utility of an end-of-trial event to reengage participants was evaluated.Results: Despite the anticipated high burden, overall trial experience was reported as highly positive. Communication and ongoing engagement between patients and both the clinical and research teams may have contributed to this. Key challenges identified for future research include the need for early and transparent communication regarding trial results, and greater support to facilitate active PPIE involvement. The end-of-trial engagement event demonstrated feasibility and value as a model to gather this important PPIE data for future studies.Conclusions: This study highlights the importance of integrating participant perspectives to optimize trial design and delivery in future cell therapy research.","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"673-687"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12915861/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145774553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How regenerative is "regenerative"? A quantitative score to benchmark therapy performance across tissues. “再生”有多再生？衡量跨组织治疗效果的定量评分。

IF 3 4区医学

Regenerative medicine Pub Date : 2025-12-01 Epub Date: 2026-02-05 DOI: 10.1080/17460751.2026.2626080

Franco Grimolizzi

{"title":"How regenerative is \"regenerative\"? A quantitative score to benchmark therapy performance across tissues.","authors":"Franco Grimolizzi","doi":"10.1080/17460751.2026.2626080","DOIUrl":"10.1080/17460751.2026.2626080","url":null,"abstract":"The term \"regenerative\" now describes an extraordinarily broad range of therapies: advanced cell and gene therapies sit alongside off-the-shelf scaffolds, injectable biologics, and topical formulations. Yet there are no agreed criteria for what regenerative means. Assessment tools that do exist focus on single tissues and were never designed to compare different product types. As a result, regenerative labeling is largely self-assigned and often binary: a product is either regenerative or it is not.This manuscript proposes the Regenerative Potential Score (RPS), a conceptual framework to quantify how regenerative a product is within a specific tissue context. The RPS looks at three aspects of regeneration: how cells respond, how much new matrix forms, and whether the product integrates functionally in vivo. Each aspect is measured using two core assays. Results are converted to standardized effect sizes and combined into a single score. The framework anchors these numbers to negative controls and current best-practice treatments, so scores reflect real clinical differences rather than arbitrary thresholds. The goal is to provide a shared language that makes comparisons more transparent and pushes the field toward consensus-based testing standards.","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"707-713"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12915804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146119743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Revolutionizing regeneration: stem cells transform treatment of hidrotic ectodermal dysplasia (Clouston syndrome). 革新再生：干细胞转化治疗多汗性外胚层发育不良（克劳斯顿综合征）。

IF 2.6 4区医学

Regenerative medicine Pub Date : 2025-12-01 Epub Date: 2025-11-24 DOI: 10.1080/17460751.2025.2593161

Asad Ullah, Ubaid Ur Rehman, Yasir Zeb, Riaz Ahmad, Faizah Salah Aljohani

{"title":"Revolutionizing regeneration: stem cells transform treatment of hidrotic ectodermal dysplasia (Clouston syndrome).","authors":"Asad Ullah, Ubaid Ur Rehman, Yasir Zeb, Riaz Ahmad, Faizah Salah Aljohani","doi":"10.1080/17460751.2025.2593161","DOIUrl":"10.1080/17460751.2025.2593161","url":null,"abstract":"Clouston syndrome is a rare autosomal dominant form of hidrotic ectodermal dysplasia that presents significant challenges due to its multisystemic manifestations and limited therapeutic options. This review explores the functional role of stem cells in the treatment and management of Clouston syndrome, highlighting advancements in regenerative medicine and stem cell therapy. Stem cell types such as mesenchymal stem cells (MSCs), epidermal stem cells (EpSCs), and induced pluripotent stem cells (iPSCs) have shown promise in regenerating ectodermal derivatives like skin, hair, and nails. Gene-editing technologies, including Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR-Cas9), can correct pathogenic mutations in the GJB6 gene. Emerging techniques in tissue engineering and three dimensional (3D) bioprinting are also discussed, focusing on their potential to create patient-specific, bioengineered constructs. Clinical trials in related genetic disorders provide evidence for the feasibility of these approaches in improving patient outcomes. However, challenges such as immune rejection, ethical concerns, and stem cell production scalability remain barriers. Addressing these issues requires interdisciplinary collaboration, sustained funding, and targeted research. This review underscores the transformative potential of regenerative medicine. It highlights the need for continued efforts to develop curative strategies for treatment, integrating stem cell-based therapies, gene editing, and bioengineering.","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"753-772"},"PeriodicalIF":2.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12915795/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145588410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancing bone repair through immunoengineering: current strategies and future directions. 通过免疫工程推进骨修复：当前策略和未来方向。

IF 3 4区医学

Regenerative medicine Pub Date : 2025-12-01 Epub Date: 2026-02-14 DOI: 10.1080/17460751.2026.2629851

Sana Pourhajrezaei, Mohammad Amin Khalili, Hamta Rahmatipoor, Jeffrey D Gross, Behina Forouzanmehr, Ali Samadi

{"title":"Advancing bone repair through immunoengineering: current strategies and future directions.","authors":"Sana Pourhajrezaei, Mohammad Amin Khalili, Hamta Rahmatipoor, Jeffrey D Gross, Behina Forouzanmehr, Ali Samadi","doi":"10.1080/17460751.2026.2629851","DOIUrl":"10.1080/17460751.2026.2629851","url":null,"abstract":"Osteogenesis and bone tissue regeneration represent complex physiological processes characterized by the orchestrated interactions between immune cells, signaling molecules, and osteoprogenitor lineages. Recent advances in immunoengineering offer innovative approaches for modulating the immune microenvironment, thereby optimizing desired regenerative outcomes in bone repair. Dysregulated immune responses, often precipitated by trauma, senescence, or pathological conditions, create inflammatory environments that can inhibit osteogenesis. This review focuses on emerging strategies in immunoengineering designed to adjust immune responses, augment osteoinductive potential, and facilitate bone tissue regeneration. Key methodologies include the functional application of biomaterial scaffolds to modulate immune cell recruitment and polarization, optimization of cytokine and chemokine delivery systems tailored for controlled release kinetics, and establishment of a pro-regenerative niche with balanced pro- and anti-inflammatory cues through scaffold engineering. Innovative methods range from immune cell reprogramming to adoptive immunotherapy, both concentrating on their capacities to modulate immune dynamics in alignment with the temporal phases of bone regeneration. By integrating principles from immunology and regenerative biology, immunoengineering offers a robust framework for advancing osteogenic strategies and holds significant translational potential for clinical applications in skeletal tissue regeneration. This review discusses in detail key immunoengineering strategies, charting a course for future advancements in osteogenic regenerative therapies.","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"737-751"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12915840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146195596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0